Drugs that contain Azilsartan Kamedoxomil
1. Drug name - EDARBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7157584 | ARBOR PHARMS LLC | Benzimidazole derivative and use thereof |
May, 2025
(2 years from now) | |
| CN101381366A | ARBOR PHARMS LLC | Benzimidazole Derivative And Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| CN101381366B | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Pharmaceutical Use |
Feb, 2025
(2 years from now) | |
| CN1946717A | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use |
Feb, 2025
(2 years from now) | |
| CN100503605C | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists |
Feb, 2025
(2 years from now) | |
| IN242537B | ARBOR PHARMS LLC | Benzimidazole Derivative And A Process For The Preparation Thereof |
Feb, 2025
(2 years from now) | |
| IN200602785P2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Use Thereof |
Feb, 2025
(2 years from now) | |
| EP2119715A1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP2119715B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A3 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1718641A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| EP1718641B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | ARBOR PHARMS LLC | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(2 years from now) | |
| US9066936 | ARBOR PHARMS LLC | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(5 years from now) | |
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG MEDOXOMIL | TABLET;ORAL | Prescription |
| EQ 80MG MEDOXOMIL | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.